| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
An influenza virus mutant induced by treating the virus with a sphydrofuran derivative (MFPT) was found to possess attenuated pathogenicity when compared with that of non-treated parent virus. Sequence analysis revealed that a mutation, P164S in NS1 protein was detected in the mutant. Nucleoprotein was found to be retained in the nuclei in the mutant virus-infected cells. It can be shown that the mutation might be one of the key residues to control NS1 function, and as a result, might be a favorable mutation in the ns gene for the attenuation of influenza virus.
When the sphydrofuran derivative was intravaginally applied to mice, the virus yields decreased dose-dependently against both herpes simplex virus types 1 and 2.
|
